Alpha-2-macroglobulin (A2M) is a powerful inhibitor of cartilage catabolic factors and stops the progression of Osteoarthritis (OA) by preventing cartilage breakdown and preventing cartilage loss.
Cytonics has developed a breakthrough molecular technology that concentrates the alpha-2-macroglobulin (A2M) in your blood to deliver high concentrations in your joint space, protecting your joint space from the destructive proteins that cause Osteoarthritis (OA).
Recent studies have shown that intra articular A2M supplementation inhibits the progression of OA by protecting the cartilage from catabolic and inflammatory factors. A2M therapy exemplifies natural healing backed by proven science that protects your joints from OA, prevents cartilage breakdown, promotes tissue growth, and supports restoration of your affected joint.
Osteoarthritis & A2M Therapy
Osteoarthritis (OA) is one of the most common health problems we face today. With nearly 30 Million Americans suffering from OA, the US Medical Expenses exceed $185.5 Billion dollars spent annually on treating conditions associated with Osteoarthritis, including knee pain, back pain, Post Traumatic OA, and many other joint conditions. Though current non-surgical Osteoarthritis (OA) treatment options show potential to offer temporary symptomatic relief, they have side effects and are ineffective at treating the root cause of OA.
Arthritic joints make several chemicals that destroy the cartilage, which is the essence of osteoarthritis. These chemicals, called catabolic proteases, work by degrading cartilage and damaging your joint by breaking down the cells.
Alpha-2-macroglobulin (A2M), found naturally in the blood, binds (captures) these “bad” chemicals produced in the knee and neutralizes their degenerative effect.
Injections of concentrated A2M is expected to be the first treatment for OA that can inhibit all causes of cartilage breakdown and thereby prevent cartilage loss, reduce pain, and stop the progression of OA.
The Autologous Protease Inhibitor Concentrate (APIC-CF) System concentrates Alpha-2- Macroglobulin (A2M) and received FDA Approval for an Investigational New Drug (IND) Clinical Trial for the treatment of mild to moderate osteoarthritis (OA) in July 2014.
1Wang, S., Wei, X., Zhou, J., Zhang, J., et. al. “Identification of α2-Macroglobulin as a Master Inhibitor of Cartilage-Degrading Factors that Attenuates the Progression of Posttraumatic Osteoarthritis.” Arthritis & Rheumatology 66.7 (2014): 1843-1853. Print.